Neuralink, Elon Musk's brain implant company, has expanded its human trials, with 12 individuals now having received its chips. This represents an increase from earlier reports, which indicated seven participants were using the implants to control various tools through thought. The company is also extending its research internationally, with plans for a clinical study in Great Britain. Furthermore, Neuralink secured significant funding, raising $650 million in a June funding round, to support its ongoing research and development.